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ABSTRACT
The avian influenza viruses of H6N1subtype present a potential danger for humans. The cold-adapted (ca) reassortant influenza 
virus А/17/herring gull/Sarma/2006/887 (H6N1) was obtained in chicken embryos by the genetic reassortment based on the cold-
adapted A/Leningrad/134/17/57 (H2N2) master strain. The genome composition of the obtained reassortant was analyzed by means 
of real-time PCR with the high resolution melting (HRM) analysis using the intercalating fluorescent dye EvaGreen. Analysis 
of the gene segments showed that the reassortant А/17/herring gull/Sarma/2006/887 (H6N1) contains the internal proteins 
coding genes (PB2, PB1, PA, NP, M, and NS) of the master donor virus and the surface antigens coding genes of the A/herring 
gull/Sarma/51c/2006 (H6N1) avian influenza virus. The study of the phenotypic properties showed that the virus А/17/herring 
gull/Sarma/2006/887 (H6N1) is temperature sensitive (ts), ca in chicken embryos, and attenuated in mice when administered 
intranasally. This reassortant can be recommended as a live influenza vaccine candidate for humans.
INTRODUCTION
The influenza viruses of H6N1 subtype that have recently 
been isolated from wild and domestic birds belong to the 
family Orthomyxoviridae to the genus Influenzavirus A. 
Until now, there were no registered severe cases of 
infection in humans with this type of viruses. However, 
the serological studies in Southern China revealed that 
13% of the inhabitants from different provinces have 
antibodies to the influenza virus of H6 subtype [1]. 
Phylogenic analysis of influenza A viruses indicate that 
the closely related genes coding the internal proteins 
could be found in influenza A viruses of different subtypes, 
and that the reassortment between the avian and human 
influenza viruses is possible [2]. It was also shown that 
some of the fragments of the NP and NA genes of highly 
pathogenic H5N1 viruses originated from the H6 virus of 
wild ducks [3, 4]. Therefore, the avian influenza viruses 
of H6N1subtype present a potential danger for humans. 
This necessitates the development of a corresponding 
vaccine strain for the protection of humans from possible 
infection. One of the candidates for the live influenza 
vaccine (LIV) – virus A/teal/Hong Kong/97/AA (H6N1) – 
was obtained on the basis of the A/Ann Arbor/6/60 
(H2N2) master strain (donor of attenuation) (Flumist®, 
USA) using the H6N1 avian influenza virus isolated 
in 1997 [5]. However, this vaccine virus demonstrated 
poor reproduction in the respiratory tract of vaccinated 
patients and low immunogenic activity. The vaccine 
strains of the live influenza vaccine represent attenuated 
reassortant virus strains with the genome composition 
6:2. The genes coding for the hemagglutinin (HA) and 
the neuraminidase (NA) are inherited from the modern 
epidemic virus while the remaining six genes coding 
the non-glycosylated proteins – from the ca donor of 
attenuation. 
The ca A/Leningrad/134/17/57 (H2N2) (Len/17) donor 
of attenuation is licensed in the Russian Federation 
for the production of the LIV vaccine strains for the 
immunization of adults and children from 3  years old 
on [6-9]. Previously, we generated and studied the 
vaccine strains containing the surface antigens of the 
nonpathogenic avian influenza viruses of A(H5N2), 
A(H7N3), and A(H9N2) subtypes based on Len/17. The 
vaccine strains of H5N2 and H7N3 subtypes were tested 
in clinical trials and showed high immunogenic activity 
inducing the seroconversions in 54.8% and 72% of 
the patients, respectively after double immunization. 
The goal of the present research project was to obtain 
the vaccine candidate of H6N1 subtype based on the 
master strain Len/17 with the surface antigens of the 
influenza virus А/herring gull/Sarma/51с/2006 (H6N1) 
and to study its properties in vitro and in the laboratory 
animals.
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The traditional analysis of the genome composition 
of the vaccine candidates obtained by the classical 
genetic reassortment is performed by the specific 
restriction of the gene products amplified by polymerase 
chain reaction (PCR) [10] or by the multiplex PCR [11] 
with the complete sequencing of the reassortant’s 
genes. For the fast genome composition analysis of the 
potential vaccine candidates, the real-time PCR with 
the use of the hydrolysable oligonucleotide probes [12] 
and pyrosequencing is used [13]. In order to simplify 
the procedure for the vaccine candidates screening we 
suggest using PCR combined with the high-resolution 
melting curves analysis (HRM-analysis). This method 
saves time compared to the visualization of results by 
electrophoresis in the course of PCR analysis and lowers 
the risk of contamination with amplicons. Furthermore, 
this method is relatively cheap because it does not require 
the use of expensive fluorescent oligonucleotide probes. 
MATERIALS AND METHODS
Viruses
The following influenza viruses were used in this research 
project: the donor of attenuation Len/17 and the wild 
type (wt) pandemic virus A/Leningrad/134/57 (H2N2) 
(Len/wt) received from the Department of Virology of the 
Institute of Experimental Medicine, as well as the avian 
influenza virus А/herring gull/Sarma/51s/2006 (H6N1) 
(H6N1/wt) isolated by Dr. A. Lyapunov from Irkutsk State 
University. The viruses were cultivated in 10-day-old 
chicken embryos (Skvoricy, Russia). The virus infectious 
activity in the chicken embryos was determined at the 
optimal (33ºC), elevated (up to 39ºC), and lowered (up 
to 26ºC) temperatures. The 50% embryonated infectious 
dose EID50 was calculated with the use of the Reed – 
Muench method [14].
PCR with HRM-analysis
The virus RNA was isolated from 80 μl of the virus 
containing allantoic fluid by means of the QIAamp Viral 
RNA Mini Kit (Qiagen, the Netherlands). The obtained 
RNA samples were stored at -20ºC. Reverse transcription 
(RT) was performed using the reverse transcriptase of 
the leukemia Molony mouse virus (M-MulV, SibEnzyme) 
and random hexamers. The RT- PCR was conducted 
using the thermal cycler CFX96 (Bio-Rad, USA) with the 
primers developed for the genes coding internal and 
nonstructural proteins of the master strain Len/17 [10]. 
For the PB1 and PA genes, additionally the following pairs 
of primers were developed using the program Primer 3 
[15]: PB1-F781 (5’ TACTTTGTCGAAACACTAGCGA 3’), 
PB1-R952 (5’ TCCATTTGGTATTGTCTCCAG 3’), PA-F47 
(5’ GCTTCAATCCGATGATTGTCGAGC 3’), PA-R206 
(5’ ATTGACTCGCCTTGCTCATT 3’). 
The reaction was performed in 20 μl containing 10 μl 
of reaction mixture SscoFast™ EvaGreen®  Supermix 
(Bio-Rad, USA), 0.5 μMol of each primer, 4 μl of cDNA and 
pure water (RNase-free) according to the manufacturers’ 
recommendations. Melting of the PCR products was 
accomplished at temperatures from 65ºC to 95ºC with 
0.5ºC increments. HRM-analysis of the melting curves 
was performed with the help of Precision Melt Analysis 
Software, Version 1.1 (Bio-Rad, USA).
Sequencing according to the Senger method
In order to perform the partial sequencing the DNA-
copies of the PB2, PB1, PA, NP, and NA RNA segments 
were obtained using the OneStep RT-PCR Kit (Qiagen, 
the Netherlands). Following the electrophoresis of 
the DNA-copies in 1.5% agarose gel and consecutive 
purification by QIAquick PCR purification Kit (Qiagen, 
the Netherlands), the sequencing was conducted on 
DNA-analyzer ABI 3730xl using the BigDye Terminator 
v3.1 Cycle Sequencing kit (Applied Biosystems, USA). 
The processing of the nucleotide sequence data was 
performed using the 3730 Data Collection v3.0 software 
package (Applied Biosystems, USA). The partial 
nucleotide sequences of PB2, PB1 and NP genes were 
deposited to the GISAID EpiFlu database with the 
corresponding access numbers PB2-EPI774106, PB1- 
EPI774107, and NP- EPI774105. 
The determination of the origin of the surface 
antigens coding genes 
The HA origin was proved by hemagglutination inhibition 
assay (HAI) with the specific rat antisera. The origin of 
the NA gene was determined by partial sequencing of the 
gene segments obtained by RT-PCR using primers NA-F1
01 (5’ GATTAGCTCAACCCAGAAAC 3’) and NA-R605 (5’ A
GAAAAAGGAAAAGTAGTAAATCA 3’).
The investigation of the reassortant properties 
following the intranasal immunization of mice
The 10-week-old CBA mice (Rappolovo, Russia) were 
immunized intranasally under the mild ether anesthesia 
with 50 μl of virus containing allantoic fluid with 
106EID50 of virus. The sterile phosphate buffered saline 
(PBS) was used as a placebo. Animal euthanasia was 
performed according to the “Regulations for conducting 
of experiments with the use of animals”. The virus load 
in the mouse lungs and nasal turbinates (4 animals 
per group) was determined on the third day post 
immunization by titration of the corresponding organ’s 
suspension in the chicken embryos starting from the 
1:10 dilution for the lungs and from 1:2 dilution for the 
nasal turbinates. The blood samples were collected three 
weeks post immunization. The obtained sera (7 animals 
per group) were treated with the neuraminidase inhibitor 
(Denka-Seiken, Japan) and tested for the presence of 
antibodies to the vaccine virus Len17/H6 in HAI test as 
described by Rowe et al. [16]. 
Statistical analysis
The experimental data were processed using the statistical 
software package ‘Statistika’ (version 6). The comparison 
of the two independent groups was conducted using the 
nonparametric Mann-Whitney criterion. The difference 
was considered to be statistically significant at p < 0.05.
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RESULTS AND DISCUSSION
The reassortant vaccine candidate Len17/H6 was 
obtained by the classical reassortment of the avian 
influenza virus H6N1/wt and ca donor of attenuation 
Len/17 as described by Alexandrova [17]. The origin of 
the HA gene of the Len17/H6 from the avian influenza 
virus H6N1/wt was confirmed by HAI with the specific 
rat antisera. The reassortant’s NA gene is also originated 
from the H6N1/wt virus as revealed by sequencing the NA 
gene segment.
The origin of the rest genes was determined by the RT-
PCR following by HRM-analysis using the intercalating 
fluorescent dye EvaGreen. The RT-PCR with the use of 
the nonspecific DNA-binding dyes usually includes the 
analysis of the PCR products melting curves. For that, the 
temperature in the probes is gradually enhanced which 
leads to the fluorophore release from the denatured 
double-stranded DNA. The rate of the fluorescence 
change allows for determining the peak corresponding to 
the melting point of the double-stranded DNA complexes. 
The dimers of primers usually have a lower melting point 
due to their smaller size that allows distinguishing the 
amplified PCR fragments from dimers of primers and 
other nonspecific products.
The analysis of the high resolution melting curves 
suggested by Wittwer et al. [18] generates melting 
curves profiles that are specific and sensitive enough for 
distinguishing DNA with slight differences in sequence 
that makes it possible to scan the mutations, analyze 
methylation, and perform genotyping [19]. HRM-analysis 
can be used for the characterization of the samples 
based on their CG-composition and complementarity of 
the DNA sequences. The growing tendency to simplify 
the mononucleotide polymorphism analysis leads to 
the rapid development of HRM-technology. In order 
to perform the high resolution melting curves analysis 
the use of the third generation of the intercalating dyes 
such as EvaGreen, LCGreen and SYTO9 is recommended 
[20]. These dyes have low toxicity; they do not inhibit 
the PCR process and could be used in RT- PCR at higher 
concentrations than SyberGreen. This enables reaching 
a higher saturation of the double-stranded DNA with 
the dye and reduces the redistribution of the dye to the 
non-denatured areas of DNA in the course of melting. 
The HRM-analysis is used already for the detection and 
quantification of influenza viruses [21] as well as for the 
screening of the new emerging strains in the population 
[22].
The results of HRM-analysis of the Len17/H6 
reassortant internal and nonstructural proteins are shown 
in Fig. 1. The quantitative clusterization analysis for all 
positive wells was performed using the software Precision 
Melt Analysis. For the visual clusters identification, this 
software generates so-called ‘differentiation curves’ for 
every well, which shows the difference in fluorescence 
Fig. 1. HRM-analysis of the genes of the inner and nonstructural proteins for the vaccine candidate Len17/H6 and the parent viruses. The 
cumulative data from the two experiments are presented. 
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Fig. 2. The analysis of the Len17/H6 genome composition by RT-PCR with subsequent restriction analysis. The gene fragments of PB2 
(1374-1614), PB1 (740-1044), PA (900-1077), NP (886-1200), M (39-249), and NS (673-830), of the vaccine candidate Len17/H6 and the 
parent viruses were amplified by RT-PCR. The obtained PCR products of PB2, NP, M and NS genes were treated with the restriction 
endonucleases Tru 9I, Eco RI, Bst FNI and Cac8I, respectively, and analyzed by electrophoresis in the agarose gel. M – DNA marker, N – 
negative control; “+” - the fragment was treated with the corresponding restriction enzyme, “-” – no treatment with the restriction enzyme.
Fig. 3. HRM-analysis of the PB1 and PA genes of the vaccine candidate Len17/H6, parent viruses and the pandemic virus Len/wt with 
the subsequent proof of the amplified fragments by sequencing. The genes fragments of PB1 (781-952) and PA (886-1200) of the vaccine 
candidate Len17/H6, parent viruses and the pandemic virus Len/wt were amplified and the corresponding high resolution melting curves 
were compared. The amplified fragments were also sequenced and the resulting alignment is presented.
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between the well and the reference curve. The latter is 
defined as the average among all the fluorescent curves 
for the corresponding reference cluster. It is quite clear 
from the graph that the shapes of the melting curves and 
the temperature profile for the virus H6N1/wt and for the 
donor of attenuation Len/17 are different. Based on that, 
it is possible to conclude that the genes coding the inner 
and nonstructural proteins of the reassortant Len17/H6 
are inherited from the ca donor of attenuation Len/17. 
The verification of obtained data was performed by 
classical RT-PCR with the subsequent specific restriction 
analysis according to method [10]. As it is shown in Fig. 2, 
the restriction enzymes cut the DNA fragments of the 
PB2, NP, M, and NS genes of the master strain and the 
vaccine candidate that indicates the presence of specific 
nucleotides typical for the donor of attenuation (PB2 
and NS) or for the H2N2 viruses (NP and M). At the same 
time, the amplified fragments of avian influenza viruses 
are not cleaved at the same conditions. These findings 
confirm the results obtained with HRM-analysis and 
prove that the melting of the PCR products does not 
destroy the DNA duplex structure, which enables the 
analysis of the amplified fragments by other methods. 
However, as shown in Fig. 2, there is no amplification of 
the PB1 and PA fragments of H6N1/wt. In this connection, 
new primers for the PB1 and PA genes were developed in 
order to amplify the shorter fragments (781-952 and 47-
206, respectively). The origin of the PB1 and PA genes 
fragments amplified with the new primers was confirmed 
by the sequencing and HRM-analysis (Fig. 3). The data 
presented in Fig. 3 also show a clear difference between 
the melting curves for the gene fragments of the master 
strain Len/17 and Len/wt virus, which differ only by one 
nucleotide substitution.
Thereby it is proved that the reassortant Len17/H6 
acquired six genes coding the inner and nonstructural 
proteins from the donor Len/17. The search for the 
homologous sequences in GenBank performed with the 
BLAST [23] showed that the PB1 gene of H6N1/wt virus 
is the most similar (99% of homology) to the avian 
virus A/duck/Jiangxi/5945/2008 (H6N1) (GenBank 
KP287703.1), whereas the closest PA gene belongs 
to the avian virus A/duck/Guizhou/2492/2007(H6N1) 
(GenBank, CY109657.1). The comparison of the amplified 
PB1 gene sequences of the Len/17 and Len17/H6 
with the H6N1/wt revealed many differences. One of 
them is the substitution T819→A that is the part of the 
specific cleavage site and enables to distinguish these 
genes by specific restriction analysis (Fig.  3).  The 
PA gene sequenses of the reassortant and the donor 
of attenuation are also different in many positions 
when compared to the H6N1/wt, and the avian virus 
A/duck/Guizhou/2492/2007 (H6N1), but all these 
viruses contain the nucleotide C at position 107. Since 
this nucleotide is critical for the traditional restriction 
analysis it is problematic to distinguish these genes 
by this method. These results confirm the limited 
possibilities of the commonly used restriction analysis 
in the course of genotyping of the avian influenza 
virus vaccine strains made on the base of Len/17 and 
prove the necessity of new methods for the vaccine 
candidates screening. 
In the course of the cultivation of the Len17/H6 
in chicken embryos at different temperatures it was 
shown that this virus is ts and ca as well as the master 
strain Len/17 in contrast to the H6N1/wt strain. The 
difference in titers at optimal (33ºC) and elevated (39ºC) 
temperatures reached 7.0 log10EID50/ml. The difference at 
the reduced and the optimal temperatures did not exceed 
3.0 log10EID50/ml (Table 1). 
Upon the intranasal immunization of mice with the 
dose of 106 EID50 the virus Len17/H6 grew in the animals 
lungs until the titer 2.8 log10 EID50/ml that was below the 
titer of the parent H6N1/wt virus and corresponded to 
the level of reproduction of the ca master strain Len/17 
(Table 1). At the same time, the vaccine strain Len17/H6 
grew effectively in the mouse nasal turbinates, where 
the temperature is significantly lower. Moreover, the 
virus Len17/H6 caused the systemic immune response 
in mice three weeks post the single immunization 
with the antibody geometric mean titer (GMT) of 17.4. 
It should be mentioned that the vaccine candidate 
Len17/H6 demonstrated the highest immunogenicity in 
mice after the single immunization compared to other 
vaccine candidates obtained with the apathogenic avian 
influenza viruses. Therefore, the antibody GMT obtained 
in mice after the single immunization with potentially 
pandemic H5N2 vaccine candidate was 6.6 (p=0.047), 
H7N3 – 8.7 (p=0.047) and H9N2 – 5.0 (p=0.0009).
Thereby, the results of the present research showed 
that the HRM-analysis enables performing the vaccine 
candidates screening. Specific restriction analysis 
method and partial sequencing confirmed the genome 
composition of the reassortant Len17/H6, which was 
determined by HRM-analysis. Analysis of the Len17/H6 
phenotypic properties in vitro (ts and ca phenotypes) and 
in vivo (attenuation for mice and the immune response 
after the single intranasal immunization) leads to the 
Table 1. The comparison of the biological properties of the reassortant vaccine candidate Len17/H6 and the parent strains
Virus Reproduction in the chicken 
embryos, log10 EID50/ml
Virus titer in the mouse respiratory 
tract on day 3, log10 EID50/ml
GMT of 
antibodies
26ºC 33ºC 39ºC Lungs Nasal turbinates
Vaccine candidate Len17/H6 6.5±0.8 9.3±0.3 2.3±0.3 2.8±0.8 3.3±0.5 17.4
Donor of attenuation Len/17 7.9±0.7 9.3±0.5 2.2±0.6 2.3±0.7 2.5±0.9 ≤10
Wild type virus H6N1/wt 1.5±0.0 6.7±0.1 7.2±0.4 4.1±0.3 2.8±0.9 16.8
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conclusion that the vaccine candidate Len17/H6 meets 
the requirements for the LIV vaccine candidates. 
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